Magnetic Resonance Spectroscopy of Breast Cancer
Abstract
Contrast-enhanced breast Magnetic Resonance Imaging (MRI) is almost 100% sensitive for breast cancer, but is used rarely because false-positive MRI scans lead to unnecessary biopsies. Magnetic Resonance Spectroscopy (MRS) is a novel, noninvasive method that measures a functional breast cancer byproduct, choline, which might reliably distinguish cancer from benign disease. The purpose of our 3-year research program is to test the hypothesis that MRS distinguishes cancer from benign tissue. The scope of work includes identifying abnormal breast lesions on contrast-enhanced breast MRI, performing in vivo MRS to detect choline in the abnormal lesion, and obtaining cells from the tumor by needle biopsy to validate the presence of choline by a high-resolution in vitro spectroscopy scan in a chemistry laboratory. In our first year we have developed, optimized and tested in vivo andin vitro MRS scans in breast phantoms and patients using these methods, showing promising results for a novel multi-voxel MRS technique that encompasses large portions of the breast. We are now ready to initiate clinical testing in women with benign disease and breast cancers. The success of this pilot project would provide a noninvasive, independent method of distinguishing breast cancer from benign disease at the time of MRI scanning, making this powerful tool more widely available to all women.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2000
- Accession Number
- ADA389439
Entities
People
- Debra M. Ikeda
Organizations
- Stanford University